共 50 条
- [11] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020) LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E75 - E75
- [12] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020) LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : E29 - E29
- [13] Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial (vol 5, pg 597, 2017) LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11): : E7 - E7
- [14] Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial (vol 5, pg 597, 2017) LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : E5 - E5
- [17] Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial (vol 376, pg 517, 2010) LANCET, 2011, 377 (9774): : 1318 - 1318
- [18] Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1754 - 1764